Patents Examined by Mindy G Brown
  • Patent number: 10801031
    Abstract: A shuttle vector is provided which can be manipulated in various kinds of host cells, thereby providing a novel tool for the field of genetic engineering. Also provided are a prokaryotic host cell and a kit including said shuttle vector, so as to construct expression vectors which contain the target gene using the shuttle vector, thereby producing proteins in various host cells with one single vector.
    Type: Grant
    Filed: September 20, 2018
    Date of Patent: October 13, 2020
    Assignee: AGRICULTURAL TECHNOLOGY RESEARCH INSTITUTE
    Inventors: Jiunn-Horng Lin, Jyh-Perng Wang, Zeng-Weng Chen, Wen-Zheng Huang, Hung-Chih Wang, Shih-Ling Hsuan
  • Patent number: 10793913
    Abstract: Provided are methods of treating breast cancer in a subject in need thereof comprising administering to the subject an effective amount of an inhibitor of miR-105 or an inhibitor of miR-122 are provided. Also provided herein are methods of determining a level of miR-105 or a level of miR-122 in a subject that has or is at risk for developing breast cancer. The method includes obtaining a biological sample from the subject and determining a level of miR-105 or a level of miR-122 or a combination thereof in the biological sample, wherein a higher level of miR-105 or miR-122 as compared to a control indicates that the subject has or is at risk of developing breast cancer.
    Type: Grant
    Filed: March 10, 2014
    Date of Patent: October 6, 2020
    Assignee: City of Hope
    Inventors: Shizhen Emily Wang, Xiwei Wu
  • Patent number: 10787654
    Abstract: The present invention is directed to methods and compositions for genome editing and DNA targeting of proteins.
    Type: Grant
    Filed: January 23, 2015
    Date of Patent: September 29, 2020
    Assignee: NORTH CAROLINA STATE UNIVERSITY
    Inventors: Rodolphe Barrangou, Kurt M. Selle, Alexandra E. Briner
  • Patent number: 10774313
    Abstract: Described is a simple plasma-based mammalian expression system that uses the RNA dependent RNA polymerase (RDRP) enzyme systems' activity for expression of recombinant proteins or RNA from viral minigenomes and rescue of recombinant viruses from cDNAs encoding entire genome(s) of negative stranded RNA viruses for use in synthesizing recombinant viruses and developing vaccines. This system will be used for expression of recombinant proteins, therapeutic RNA molecules including anti-sense and/or selecting interfering RNA and Ribozymes. This system can also be used for gene therapy and producing recombinant viruses for production of new vaccines.
    Type: Grant
    Filed: August 5, 2016
    Date of Patent: September 15, 2020
    Inventor: Vishwas Joshi
  • Patent number: 10774389
    Abstract: This invention relates, e.g., to a method for determining if a thyroid tumor in a subject is malignant, comprising determining in a sample from the subject the amount of TERT (telomerase reverse transcriptase) mRNA which lacks the ? sequence and the amount of TERT mRNA in the sample which comprises the ? sequence, wherein a preponderance (e.g., at least about 55%) of TERT mRNA in the sample which comprises the ? sequence indicates that the tumor is malignant, and wherein a preponderance of TERT mRNA which lacks the ? sequence indicates that the tumor is not malignant.
    Type: Grant
    Filed: September 29, 2017
    Date of Patent: September 15, 2020
    Assignee: The Johns Hopkins University
    Inventors: Martha Allen Zeiger, Jeanne Kowalski, Christopher Umbricht, Yongchun Wang
  • Patent number: 10761090
    Abstract: The invention generally relates to performing sandwich assays in droplets. In certain embodiments, the invention provides methods for detecting a target analyte that involve forming a compartmentalized portion of fluid including a portion of a sample suspected of containing a target analyte and a sample identifier, a first binding agent having a target identifier, and a second binding agent specific to the target analyte under conditions that produce a complex of the first and second binding agents with the target analyte, separating the complexes, and detecting the complexes, thereby detecting the target analyte.
    Type: Grant
    Filed: January 25, 2017
    Date of Patent: September 1, 2020
    Assignee: Bio-Rad Laboratories, Inc.
    Inventors: Michael L. Samuels, Darren Roy Link
  • Patent number: 10759830
    Abstract: The disclosure provides compositions and methods for purification of proteins, including multi-subunit complexes and membrane proteins. Modified colicin-DNAse domains and modified colicin immunity proteins are provided for use in purification methods. Also provided are related nucleic acids, vectors, genetically modified cells and affinity matrices.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: September 1, 2020
    Assignee: THE UAB RESEARCH FOUNDATION
    Inventors: Dmitry Vassylyev, Norman Patrick Higgins, Marina Vassylyeva, Alexey Vasiliev
  • Patent number: 10752928
    Abstract: Disclosed are whole-cell catalysts, methods of making the whole-cell catalysts, and methods of using the whole-cell catalysts to produce steviol glycosides.
    Type: Grant
    Filed: April 14, 2016
    Date of Patent: August 25, 2020
    Assignee: Conagen Inc.
    Inventors: Guohong Mao, Jacob Edward Vick, Shi-Yan Li, Xiaodan Yu
  • Patent number: 10745744
    Abstract: The disclosed Hi-C protocol can identify genomic loci that are spatially co-located in vivo. These spatial co-locations may include, but are not limited to, intrachromosomal interactions and/or interchromosomal interactions. Hi-C techniques may be applied to many different scales of interest. For example, on a large scale, Hi-C techniques can be used to identify long-range interactions between distant genomic loci.
    Type: Grant
    Filed: June 15, 2017
    Date of Patent: August 18, 2020
    Assignees: University of Massachusetts, Massachusetts Institute of Technology, President and Fellows of Harvard College, Whitehead Institute for Biomedical Research
    Inventors: Job Dekker, Erez Lieberman Aiden, Nynke Van Berkum, Andreas Gnirke, Eric Lander, Chad Nusbaum, Louise Williams, Alexandre Melnikov, Georgia Giannoukos
  • Patent number: 10745730
    Abstract: The present invention describes host cells for reliable, high yield recombinant protein production, including unstable proteins. The present host cell (e.g., a bacterial cell) is deficient in at least one protease (or a subunit of a protease) such as Clp or ClpP. The host cell may also contain an expression vector that encodes a protein or polypeptide for overexpression.
    Type: Grant
    Filed: September 28, 2016
    Date of Patent: August 18, 2020
    Assignee: The Trustees of Columbia University of the City of New York
    Inventor: Maxwell Gottesman
  • Patent number: 10745731
    Abstract: Herein is reported a method for the recombinant production of a polypeptide in a eukaryotic cell comprising the steps of (i) cultivating a eukaryotic cell comprising a nucleic acid encoding the polypeptide in a cultivation medium comprising a compound selected from the group consisting of trans-2-methyl 2-pentenoic acid, the broad-spectrum HDAC inhibitor Quisinostat, and the subtype-specific HDAC inhibitor Romidepsin, and (ii) recovering the polypeptide from the cell or the cultivation medium and thereby producing the polypeptide in a eukaryotic cell.
    Type: Grant
    Filed: June 11, 2018
    Date of Patent: August 18, 2020
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Tobias Killian, Markus Neubauer
  • Patent number: 10738284
    Abstract: Variant B4GALT1 genomic, mRNA, and cDNA nucleic acid molecules, and polypeptides, methods of detecting the presence of these molecules, methods of modulating endogenous B4GALT1 genomic, mRNA, and cDNA nucleic acid molecules, and polypeptides, methods of ascertaining the risk of developing cardiovascular conditions by detecting the presence or absence of the variant B4GALT1 genomic, mRNA, and cDNA nucleic acid molecules, and polypeptides, and methods of treating cardiovascular conditions are provided herein.
    Type: Grant
    Filed: June 4, 2018
    Date of Patent: August 11, 2020
    Assignees: Regeneron Pharmaceuticals, Inc., University of Maryland, Baltimore
    Inventors: May Montasser, Cristopher Van Hout, Alan Shuldiner, Giusy Della Gatta, Matthew Healy, Marja Puurunen
  • Patent number: 10732171
    Abstract: Human skin tissue sample methods and models for identifying and screening test agents as effective for providing skin tone benefits, methods for validating hypotheses for mechanisms driving skin pigmentation as well as methods for driving skin pigment levels in ex-vivo skin tissue. The method includes contacting a cultured human skin tissue sample with a test agent, generating a transcriptional profile from the sample, and comparing the results to a control to determine if the test agent is effective for providing a skin tone benefit.
    Type: Grant
    Filed: December 20, 2012
    Date of Patent: August 4, 2020
    Assignee: The Procter & Gamble Company
    Inventors: Deborah Ruth Finlay, Tomohiro Hakozaki, Charles Carson Bascom, Heather Eileen Matheny
  • Patent number: 10711281
    Abstract: The present invention relates to adeno-associated viral vector useful for transducing adipose tissue. The invention also relates to polynucleotides, plasmids, vectors and methods for the production of such adeno-associated viral vector. The invention also relates to gene therapy methods useful for the treatment of a disease that requires the regulation of the expression levels of a gene.
    Type: Grant
    Filed: August 2, 2013
    Date of Patent: July 14, 2020
    Assignee: Universitat Autónoma de Barcelona
    Inventors: Verónica Jiménez Cenzano, Fátima Bosch Tubert
  • Patent number: 10711275
    Abstract: Disclosed are methods and compositions for inhibiting DNA synthesis in a cell using RNA. Inhibition of DNA synthesis by RNA can be used, for example, in analytical methods, as a research tool to affect cells under study, to synchronize cell cycle in a cell culture, and to inhibit cell growth. For example, inhibition of DNA synthesis in cancer cells can be used to inhibit cancer cells and treat cancer. The RNA can be any RNA, such as whole cell RNA, whole cell mRNA, whole cell ribosomal RNA, whole cell transfer RNA, synthetic RNA, recombinant RNA, modified RNA, or a combination. The composition can comprise RNA and a pharmaceutically acceptable carrier or RNA, a targeting molecule, and a pharmaceutically acceptable carrier. The targeting molecule can be a tumor-targeting peptide.
    Type: Grant
    Filed: July 11, 2014
    Date of Patent: July 14, 2020
    Inventor: Zhen Huang
  • Patent number: 10711267
    Abstract: This invention relates to recombinant Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) arrays and recombinant nucleic acid constructs encoding Type I-E CASCADE complexes as well as plasmids, retroviruses and bacteriophage comprising the same.
    Type: Grant
    Filed: September 25, 2019
    Date of Patent: July 14, 2020
    Assignee: NORTH CAROLINA STATE UNIVERSITY
    Inventors: Rodolphe Barrangou, Claudio Hidalgo-Cantabrana
  • Patent number: 10689640
    Abstract: The present invention provides an array for rapidly identifying a host cell population capable of producing a heterologous recombinant protein with improved yield and/or quality. The array comprises one or more host cell populations that have been genetically modified to increase the expression of one or more target genes involved in protein production, decrease the expression of one or more target genes involved in protein degradation, or both. One or more of the strains in the array may express the heterologous recombinant protein of interest in a periplasm compartment or may secrete the heterologous recombinant protein extracellularly through an outer cell wall. The strain arrays are useful for screening for improved expression of any protein of interest including therapeutic proteins, hormones, growth factors, extracellular receptors or ligands, proteases, kinases, blood proteins, chemokines, cytokines, antibodies and the like.
    Type: Grant
    Filed: December 19, 2016
    Date of Patent: June 23, 2020
    Assignee: Pfenex Inc.
    Inventors: Diane M. Retallack, Charles H. Squires, Thomas M. Ramseier, Russell J. Coleman, Jane C. Schneider, Charles D. Hershberger
  • Patent number: 10682378
    Abstract: The invention is directed to T cells and other cells that express chimeric NK-p30 receptors (“chimeric NKp30 T cells”), methods of making and using chimeric NKp30 T cells, and methods of using these chimeric NKp30 T cells, isolated populations thereof, and compositions comprising the same. In another aspect, said chimeric NKp30 T cells are further designed to express a functional non-TCR receptor. The disclosure also pertains to methods of making said chimeric NKp30 T cells, and methods of reducing or ameliorating, or preventing or treating, diseases and disorders using said chimeric NKp30 T cells, populations thereof, or compositions comprising the same.
    Type: Grant
    Filed: December 4, 2017
    Date of Patent: June 16, 2020
    Assignee: THE TRUSTEES OF DARTMOUTH COLLEGE
    Inventors: Tong Zhang, Charles L. Sentman
  • Patent number: 10676721
    Abstract: The present invention is generally related to engineered bacteriophages expressing antimicrobial peptides or lytic enzymes or fragments thereof for targeting a broad spectrum of bacterial hosts, and for the long-term suppression of bacterial phage resistance for reducing bacterial infections. In some embodiments, bacteriophages express antimicrobial peptides or antimicrobial polypeptides (e.g. phage lytic enzymes) which are secreted from the host bacteria, or alternatively released upon lysis of the bacterial host cell. Aspects of the present invention also relate to the use of the engineered bacteriophages for the reduction of bacterial infections, both in a subject or for bioremediation purposes, in clinical settings and wound healing.
    Type: Grant
    Filed: September 2, 2011
    Date of Patent: June 9, 2020
    Assignees: Trustees of Boston University, Massachusetts Institute of Technology
    Inventors: James J. Collins, Michael Koeris, Timothy Kuan-Ta Lu, Gregory Stephanopoulos, Christopher Jongsoo Yoon
  • Patent number: 10669550
    Abstract: The invention discloses a promoter which can be induced to express in acidic conditions, and relates to the field of bioengineering technology. The promoters of the invention are separated from A. niger and can actuate and/or regulate the expression of the effectively connected nucleic acids in A. niger. In the invention the expression of the promoters is studied in A. niger, and it is indicated that some promoters show weak expression, and some show strong activity. The invention provides an effective method and new thought for organic acids production by fungi or other products produced by fermentation under acidic conditions.
    Type: Grant
    Filed: January 28, 2019
    Date of Patent: June 2, 2020
    Assignee: JIANGNAN UNIVERSITY
    Inventors: Long Liu, Jian Chen, Guocheng Du, Xian Yin, Jianghua Li